ZA906186B - Pharmaceutical preparations - Google Patents

Pharmaceutical preparations

Info

Publication number
ZA906186B
ZA906186B ZA906186A ZA906186A ZA906186B ZA 906186 B ZA906186 B ZA 906186B ZA 906186 A ZA906186 A ZA 906186A ZA 906186 A ZA906186 A ZA 906186A ZA 906186 B ZA906186 B ZA 906186B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Application number
ZA906186A
Other languages
English (en)
Inventor
Maria Oksana Bachynsky
Oksana Bachynsky Maria
Alberto Davidovich
Davidovich Alberto
Martin Howard Infeld
Howard Infeld Martin
Navnit Shah
Shah Navnit
Joel Unowsky
Unowsky Joel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA906186B publication Critical patent/ZA906186B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA906186A 1989-09-11 1990-08-06 Pharmaceutical preparations ZA906186B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40549489A 1989-09-11 1989-09-11

Publications (1)

Publication Number Publication Date
ZA906186B true ZA906186B (en) 1991-06-26

Family

ID=23603936

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA906186A ZA906186B (en) 1989-09-11 1990-08-06 Pharmaceutical preparations

Country Status (8)

Country Link
EP (1) EP0418674A1 (xx)
JP (1) JPH03106827A (xx)
AU (1) AU6236090A (xx)
CA (1) CA2024887A1 (xx)
HU (1) HU207216B (xx)
IE (1) IE903285A1 (xx)
IL (1) IL95614A0 (xx)
ZA (1) ZA906186B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136105A (en) * 1991-03-28 1992-08-04 Union Carbide Chemicals & Plastics Technology Corporation Oxidation of terminal olefins to aldehydes
SI9400338A (en) * 1994-08-31 1996-04-30 Lek D D Vancomycin hydrochloride suspensions for peroral use and for filling into soft ,gelatine capsules.
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB2318056B (en) * 1995-08-08 1999-05-26 Danbiosyst Uk Composition for enhanced uptake of polar drugs from the colon
JP2007042005A (ja) * 2005-08-05 2007-02-15 Toppan Forms Co Ltd メールアドレス収集方法、情報処理サーバおよびメールアドレス収集システム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
EP0126348A2 (en) * 1983-05-19 1984-11-28 Kyoto Pharmaceutical Industries, Ltd. Composition for rectal administration and method of promoting rectal drug absorption
CA1256799A (en) * 1984-02-22 1989-07-04 Walter Fuller Suppositories

Also Published As

Publication number Publication date
CA2024887A1 (en) 1991-03-12
HUT56269A (en) 1991-08-28
AU6236090A (en) 1991-03-14
HU905823D0 (en) 1991-03-28
JPH03106827A (ja) 1991-05-07
EP0418674A1 (de) 1991-03-27
IE903285A1 (en) 1991-04-10
HU207216B (en) 1993-03-29
IL95614A0 (en) 1991-06-30

Similar Documents

Publication Publication Date Title
ZA902519B (en) Pharmaceutical formulations
GB8719375D0 (en) Pharmaceutical preparations
ZA906186B (en) Pharmaceutical preparations
GB8906129D0 (en) Pharmaceutical preparations
GB8917959D0 (en) Pharmaceutical formulation
ZA899948B (en) Pharmaceutical preparation
CS343490A3 (en) Pharmaceutical
GB8914613D0 (en) Pharmaceutical preparations
IE890944L (en) Pharmaceutical preparations
GB8914611D0 (en) Pharmaceutical preparations
GB8914610D0 (en) Pharmaceutical preparations
GB8914612D0 (en) Pharmaceutical preparations
IE890022L (en) Pharmaceutical preparations
IE892741L (en) Pharmaceutical combination preparations
ZA875281B (en) Zylometzoline-containing pharmaceutical preparations
GB9014367D0 (en) Pharmaceutical preparations
GB9014365D0 (en) Pharmaceutical preparations
GB9014354D0 (en) Pharmaceutical preparations
GB9014364D0 (en) Pharmaceutical preparations
IE901759L (en) Pharmaceutical preparations
GB8921595D0 (en) Pharmaceutical preparation
GB8701271D0 (en) Pharmaceutical preparations
IE871199L (en) Pharmaceutical preparations
IE873302L (en) Pharmaceutical preparations
GB8603271D0 (en) Pharmaceutical preparations